Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Exploring Innovative Approaches Throughout the CGT Development Journey
A Concise Report Featuring Insights From The Prominent Thought Leaders Of Cell UK
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Antibody & Protein Engineering
AbbVie Ditch Phase II Autoimmune Drug
AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva
Manufacturing & Bioprocessing
Overcoming the Challenges in Cell Therapy Manufacturing
Udayanath Aich, Director at Bristol Myers Squibb, leads a Discussion Group on leveraging advanced technologies and biologics to mitigate challenges.
NextGen Therapeutics
Exploring & Developing Various Biotherapeutic Modalities
Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.
Manufacturing & Bioprocessing
Looking into the Crystal Ball: The Future of Disruptive Cell and Gene Therapy Manufacturing
What will the future hold for autologous cell and gene therapy manufacturing? Tigen Pharma SA, share their predictions on the prospect of disruptive innovation for the industry.
3-Dose Hepatitis B Vaccine Offers Full Protection for People with HIV
Phase III clinical trials from the University of Cincinnati have shown seroprotection in 100% of HIV-positive participants after a 3-dose regimen of the HEPLISAV-B vaccine.
Manufacturing & Bioprocessing
AAV Manufacturing Using Osmolality
New Data from the Cell and Gene Therapy Catapult shows improved yield, quality, and process efficiency for AAV manufacturing using osmolality.
Antibody & Protein Engineering
Oxford Global's R&D Key 40 Stories 2022
Download a copy of the R&D Key 40 Stories 2022 eBook today.
Bioanalysis
Mass Spectrometry: Shortening Time Scales and Progressing Towards Automation
Discover the top bioanalysis presentations from Biologics UK 2022.
Drug Discovery & Development
T Cell Enhancers: Conditional Activation for a Safe and Durable Response
Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.
NextGen Therapeutics
Gilead Pay Big Bucks for MacroGenics' Blood-Cancer Targeting Bispecific
Gilead announced a $1.7 billion licence-option deal for MacroGenics’ MGD024 bispecific once Phase I trials conclude.
Immunotherapy (Non-Oncology)
Immunology: from Cancer to COVID
Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19.
Bioanalysis
Turbocharging Potency Assays – Challenges and Opportunities from Multispecific Drug Modalities
The development of multispecific drugs is an inherently complex and challenging process. Barbara Hebeis of AstraZeneca talks us through challenges surrounding the development of appropriate potency assays, and the opportunities the field offers.